Biopharma M&A

Recent deal announcements covering the last 60 days. Deal activity continues to be strong, led by Pfizer’s winning $14 billion bid for Medivation over the likes of Sanofi and Gilead.   Biopharma M&A

By | September 20th, 2016|M&A, Uncategorized|Comments Off on Biopharma M&A

Nivolumad Therapy in Kidney Cancer

The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting. This is terrific for patients of this difficult disease, as well as for Bristol-Meyers Squibb who markets Optivo.   Nivolumad therapy in kidney cancer    

By | September 20th, 2016|BMS, Cancer|Comments Off on Nivolumad Therapy in Kidney Cancer